Motus GI (NASDAQ:MOTS – Get Rating) had its price target cut by HC Wainwright from $11.00 to $10.00 in a research report sent to investors on Tuesday, The Fly reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Motus GI’s Q4 2022 earnings at ($1.25) EPS, FY2022 earnings at ($6.51) EPS, Q1 2023 earnings at ($1.06) EPS, Q2 2023 earnings at ($1.03) EPS, Q3 2023 earnings at ($0.83) EPS, Q4 2023 earnings at ($0.69) EPS and FY2023 earnings at ($3.52) EPS.
Several other research firms have also weighed in on MOTS. Piper Sandler dropped their price target on Motus GI from $10.00 to $6.00 and set an overweight rating on the stock in a research report on Monday, November 14th. Alliance Global Partners dropped their price target on Motus GI from $24.00 to $12.00 in a research report on Thursday, August 11th.
Motus GI Stock Up 2.9 %
NASDAQ:MOTS opened at $1.42 on Tuesday. The firm has a market capitalization of $4.26 million, a price-to-earnings ratio of -0.19 and a beta of 1.85. Motus GI has a 1-year low of $1.38 and a 1-year high of $13.00. The company has a current ratio of 2.83, a quick ratio of 4.03 and a debt-to-equity ratio of 11.98. The business’s fifty day moving average price is $2.14 and its 200 day moving average price is $3.86.
Institutional Trading of Motus GI
About Motus GI
Motus GI Holdings, Inc, a medical technology company, develops Pure-Vu system, a medical device to facilitate the cleaning of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedure. The company was incorporated in 2016 and is based in Fort Lauderdale, Florida.
- Get a free copy of the StockNews.com research report on Motus GI (MOTS)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML’s November Rally Have Staying Power?
Receive News & Ratings for Motus GI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motus GI and related companies with MarketBeat.com's FREE daily email newsletter.